Table 2. Analysis of comorbidities' influence on protein levels in the aneurysm group.
| Comorbidity/Medication | Protein | p-value |
|---|---|---|
| Hypertension | Pro-MMP-2 | 0.773 |
| Active MMP-2 | 0.256 | |
| Total MMP-2 | 0.290 | |
| MMP-14 | 0.301 | |
| TIMP-2 | 0.879 | |
| Hyperlipidemia | Pro-MMP-2 | 0.120 |
| Active MMP-2 | 0.009 | |
| Total MMP-2 | 0.097 | |
| MMP-14 | 0.990 | |
| TIMP-2 | 0.247 | |
| Diabetes mellitus | Pro-MMP-2 | 0.412 |
| Active MMP-2 | 0.861 | |
| Total MMP-2 | 0.884 | |
| MMP-14 | 0.617 | |
| TIMP-2 | 0.908 | |
| Anticoagulation | Pro-MMP-2 | 1.000 |
| Active MMP-2 | 0.267 | |
| Total MMP-2 | 0.770 | |
| MMP-14 | 0.699 | |
| TIMP-2 | 0.457 |